Efficacy and Safety of Tofacitinib in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Real-World Study
Tofacitinib demonstrated significant clinical benefit in RA patients with inadequate MTX response, with acceptable safety. While machine learning highlighted key predictors, future work with larger datasets is needed to optimize predictive accuracy and personalize therapy.
Authors
- Abdullah Elrefae (ORCID: https://orcid.org/0000-0002-3739-4045)
- Khawaja Faizan Ejaz
- Jazba Yousaf
- Monther Qandeel (ORCID: https://orcid.org/0000-0002-7176-4214)
- Rehan Wani (ORCID: https://orcid.org/0000-0001-5338-7809)
- Ammarah Amjad
- Adeel Abbas Raja
- Muhammad Iftikhar Khattak
- Sajid Naseem
- Amaan A Zai
Institutions
- Nottingham University Hospitals NHS Trust (GB)
- University of Azad Jammu and Kashmir (PK)
- Rawalpindi Medical University (PK)
- Russells Hall Hospital (GB)
- Dow University of Health Sciences (PK)
- Advanced Media Research (United States) (US)
- Central Middlesex Hospital (GB)
- Pakistan Institute of Medical Sciences (PK)
- Institute of Medical Sciences (IN)
Publication Details
- Journal
- Cureus
- Published
- 2025-10-16
- DOI
- https://doi.org/10.7759/cureus.94745
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00